Ergonovine
| Ergonovine | |
|---|---|
| Salts [] | |
|---|---|
| Ergonovine maleate | |
| Ergonovine hemitartrate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 325.40 g/mol [1] |
| Appearance | Plates or needles [1] |
| Melting point | 162 °C [1] |
| Decomposition | When heated to decomposition it emits toxic fumes of /nitrogen oxides/. [1] |
| Solubility | 2.68 mg/mL at 25 °C [1] |
| Predicted LogP | 1.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C19H23N3O2 |
| IUPAC name | (6aR,9R)-N-[(2S)-1-hydroxypropan-2-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide |
| SMILES | C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C |
| InChI | InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1 |
| InChIKey | WVVSZNPYNCNODU-XTQGRXLLSA-N |
| CAS number | 60-79-7 |
| UNII | WH41D8433D |
| PubChem CID | 443884 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 2-phase (10 min; 2 hours) |
| Metabolism | Liver (partly CYP3A4) |
| Excretion | Bile duct |
| Routes of administration | oral, intramuscular, intravenous |
Ergonovine (also known as Ergobasine, Ergotocine, Ergostetrine, Margonovine, Ergoklinine, Ergometrin, Ergometrina, Secacornin, Ergometrinum or Secometrin) is a substance of the lysergamide class.
Chemistry
Salts []
Stereochemistry []
Ergonovine is a single defined stereoisomer.
Druglikeness
Lipinski's rule of five
Ergonovine matches Lipinski's rule of five.Reagents
There are currently 2 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Ehrlich | purple | |
| Hofmann | blue |
Pharmacology
ATC Classification
- genito urinary system and sex hormones (G)
- other gynecologicals (G02)
- uterotonics (G02A)
- ergot alkaloids (G02AB)
- (G02AB03)
- ergometrine (G02AB03)
MeSH Classification
- oxytocics (M0015702)
Mechanism of action []
Ergonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental site produces hemostasis. Ergonovine also induces cervical contractions. The sensitivity of the uterus to the oxytocic effect is much greater toward the end of pregnancy. The oxytocic actions of ergonovine are greater than its vascular effects. Ergonovine, like other ergot alkaloids, produces arterial vasoconstriction by stimulation of alpha-adrenergic and serotonin receptors and inhibition of endothelial-derived relaxation factor release. It is a less potent vasoconstrictor than ergotamine. As a diagnostic aid (coronary vasospasm), ergonovine causes vasoconstriction of coronary arteries. [1]
Interactions []
Medical side effects []
36 side effects listed on drug labels in SIDER 4.1 (ergonovine).
- Abdominal pain
- Gastrointestinal pain
- Chest pain
- Arteriospasm coronary
- Diarrhoea
- Dizziness
- Dyspnoea
- Oesophageal spasm
- Gangrene
- Hallucination
- Headache
- Haematuria
- Hypertension
- Hypotension
- Muscle spasms
- Myasthenia gravis
- Myocardial infarction
- Acute coronary syndrome
- Nasal congestion
- Nausea
- Palpitations
- Pulmonary oedema
- Shock
- Hyperhidrosis
- Thrombophlebitis
- Tinnitus
- Vertigo
- Vomiting
- Water intoxication
- Ventricular arrhythmia
- Vasospasm
- Intestinal infarction
- Pleural fibrosis
- Bradycardia
- Drug interaction
- Intestinal ischaemia
Indications
- Post abortion haemorrhage
- Postpartum haemorrhage
- Uterine atony
Legal status []
- Brazil: Ergonovine is a D1.[3]
- Canada: Ergonovine is a Schedule VI.
- United States: Ergonovine is a Rx only.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 443884, Ergonovine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/443884
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Ergonovine. UNII: WH41D8433D. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/WH41D8433D
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 03:05:37 |
| drugspro | ok | 2026-11-20 03:05:33 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 03:05:33 |
| gsrs | ok | 2026-11-20 03:05:35 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0015383) | 2026-11-20 03:05:33 |
| kegg | ok | 2026-11-20 03:05:35 |
| pubchem | ok | 2026-11-20 03:05:33 |
| missing (no r/tripreports posts mention it) | 2026-11-20 03:05:33 | |
| sider | ok | 2026-11-20 03:05:33 |
| structure | ok | 2026-11-20 03:05:33 |
| wikipedia | ok | 2026-11-20 03:05:34 |